Stephan Grupp
#116,103
Most Influential Person Now
American pediatric oncologist
Stephan Grupp's AcademicInfluence.com Rankings
Stephan Gruppphilosophy Degrees
Philosophy
#6307
World Rank
#9322
Historical Rank
Logic
#3483
World Rank
#4649
Historical Rank
Download Badge
Philosophy
Stephan Grupp's Degrees
- Doctorate Medicine University of Pennsylvania
- PhD Immunology University of Pennsylvania
Why Is Stephan Grupp Influential?
(Suggest an Edit or Addition)According to Wikipedia, Stephan A. Grupp is an American pediatric oncologist. He is the Chief of the Cell Therapy and Transplant Section in the Division of Oncology and Director of the Cancer Immunotherapy Program at the Children's Hospital of Philadelphia and Professor of Pediatrics at the Perelman School of Medicine at the University of Pennsylvania. In 2019, Grupp was elected a Member of the National Academy of Medicine.
Stephan Grupp's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Chimeric antigen receptor T cells for sustained remissions in leukemia. (2014) (4010)
- Tisagenlecleucel in Children and Young Adults with B‐Cell Lymphoblastic Leukemia (2018) (2931)
- Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. (2013) (2847)
- T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced Leukemia (2011) (2173)
- Current concepts in the diagnosis and management of cytokine release syndrome. (2014) (1921)
- Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. (2010) (1385)
- Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia (2015) (1326)
- ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells. (2018) (1270)
- Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo. (2009) (985)
- Convergence of Acquired Mutations and Alternative Splicing of CD19 Enables Resistance to CART-19 Immunotherapy. (2015) (865)
- Identification of Predictive Biomarkers for Cytokine Release Syndrome after Chimeric Antigen Receptor T-cell Therapy for Acute Lymphoblastic Leukemia. (2016) (730)
- Genetic alterations activating kinase and cytokine receptor signaling in high-risk acute lymphoblastic leukemia. (2012) (661)
- Managing Cytokine Release Syndrome Associated With Novel T Cell-Engaging Therapies (2014) (620)
- Antibody-modified T cells: CARs take the front seat for hematologic malignancies. (2014) (576)
- CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia. (2015) (565)
- Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy. (2013) (506)
- CRISPR-Cas9 Gene Editing for Sickle Cell Disease and β-Thalassemia. (2020) (449)
- ‘Off-the-shelf’ allogeneic CAR T cells: development and challenges (2020) (435)
- Dual CD19 and CD123 targeting prevents antigen-loss relapses after CD19-directed immunotherapies. (2016) (409)
- Preclinical targeting of human acute myeloid leukemia and myeloablation using chimeric antigen receptor-modified T cells. (2014) (382)
- Induction of resistance to chimeric antigen receptor T cell therapy by transduction of a single leukemic B cell (2018) (374)
- Genetic mechanisms of target antigen loss in CAR19 therapy of acute lymphoblastic leukemia (2018) (327)
- Chimeric antigen receptor therapy for cancer. (2014) (325)
- Cytokine Release Syndrome After Chimeric Antigen Receptor T Cell Therapy for Acute Lymphoblastic Leukemia (2017) (315)
- Grading of cytokine release syndrome associated with the CAR T cell therapy tisagenlecleucel (2018) (295)
- Targeting JAK1/2 and mTOR in murine xenograft models of Ph-like acute lymphoblastic leukemia. (2012) (270)
- Multisystem inflammatory syndrome in children and COVID-19 are distinct presentations of SARS-CoV-2. (2020) (252)
- Antitumor Activity Associated with Prolonged Persistence of Adoptively Transferred NY-ESO-1 c259T Cells in Synovial Sarcoma. (2018) (243)
- Cellular kinetics of CTL019 in relapsed/refractory B-cell acute lymphoblastic leukemia and chronic lymphocytic leukemia. (2017) (226)
- Phase 3 trial of defibrotide for the treatment of severe veno-occlusive disease and multi-organ failure. (2016) (222)
- Purged versus non-purged peripheral blood stem-cell transplantation for high-risk neuroblastoma (COG A3973): a randomised phase 3 trial. (2013) (221)
- Early memory phenotypes drive T cell proliferation in patients with pediatric malignancies (2016) (208)
- High-risk neuroblastoma treated with tandem autologous peripheral-blood stem cell-supported transplantation: long-term survival update. (2006) (190)
- Efficacy of JAK/STAT pathway inhibition in murine xenograft models of early T-cell precursor (ETP) acute lymphoblastic leukemia. (2015) (185)
- Adoptive transfer of costimulated T cells induces lymphocytosis in patients with relapsed/refractory non-Hodgkin lymphoma following CD34+-selected hematopoietic cell transplantation. (2003) (183)
- Treatment of advanced leukemia in mice with mRNA engineered T cells. (2011) (180)
- Real-world evidence of tisagenlecleucel for pediatric acute lymphoblastic leukemia and non-Hodgkin lymphoma. (2020) (170)
- The mTOR inhibitor CCI-779 induces apoptosis and inhibits growth in preclinical models of primary adult human ALL. (2006) (166)
- Rapamycin is active against B-precursor leukemia in vitro and in vivo, an effect that is modulated by IL-7-mediated signaling (2003) (166)
- Tacrolimus/sirolimus vs tacrolimus/methotrexate as GVHD prophylaxis after matched, related donor allogeneic HCT. (2014) (161)
- IgH-V(D)J NGS-MRD measurement pre- and early post-allotransplant defines very low- and very high-risk ALL patients. (2015) (161)
- Unmasking Evans syndrome: T-cell phenotype and apoptotic response reveal autoimmune lymphoproliferative syndrome (ALPS). (2004) (161)
- Effect of Tandem Autologous Stem Cell Transplant vs Single Transplant on Event-Free Survival in Patients With High-Risk Neuroblastoma: A Randomized Clinical Trial. (2019) (160)
- High-Affinity GD2-Specific CAR T Cells Induce Fatal Encephalitis in a Preclinical Neuroblastoma Model (2017) (159)
- Sirolimus is effective in relapsed/refractory autoimmune cytopenias: results of a prospective multi-institutional trial. (2016) (154)
- Chimeric antigen receptor (CAR) T therapies for the treatment of hematologic malignancies: clinical perspective and significance (2018) (150)
- Treatment with sirolimus results in complete responses in patients with autoimmune lymphoproliferative syndrome (2009) (148)
- Measuring IL-6 and sIL-6R in serum from patients treated with tocilizumab and/or siltuximab following CAR T cell therapy. (2016) (147)
- Chimeric Antigen Receptor– and TCR-Modified T Cells Enter Main Street and Wall Street (2015) (145)
- RNA-transfected CD40-activated B cells induce functional T-cell responses against viral and tumor antigen targets: implications for pediatric immunotherapy. (2004) (145)
- Reducing Ex Vivo Culture Improves the Antileukemic Activity of Chimeric Antigen Receptor (CAR) T Cells (2018) (139)
- Preclinical efficacy of daratumumab in T-cell acute lymphoblastic leukemia. (2018) (138)
- Phase II trial of temsirolimus in children with high-grade glioma, neuroblastoma and rhabdomyosarcoma. (2010) (134)
- Toxicity management for patients receiving novel T-cell engaging therapies (2014) (133)
- Clinical Pharmacology of Tisagenlecleucel in B-cell Acute Lymphoblastic Leukemia (2018) (132)
- Impaired death receptor signaling in leukemia causes antigen-independent resistance by inducing CAR T cell dysfunction. (2020) (130)
- Optimized depletion of chimeric antigen receptor T cells in murine xenograft models of human acute myeloid leukemia. (2017) (128)
- Durable Remissions in Children with Relapsed/Refractory ALL Treated with T Cells Engineered with a CD19-Targeted Chimeric Antigen Receptor (CTL019) (2015) (128)
- Naïve T-cell Deficits at Diagnosis and after Chemotherapy Impair Cell Therapy Potential in Pediatric Cancers. (2019) (127)
- Sustained remissions with CD19-specific chimeric antigen receptor (CAR)-modified T cells in children with relapsed/refractory ALL. (2016) (126)
- The Future Is Now: Chimeric Antigen Receptors as New Targeted Therapies for Childhood Cancer (2012) (125)
- mTOR inhibitors are synergistic with methotrexate: an effective combination to treat acute lymphoblastic leukemia. (2008) (123)
- Potent efficacy of combined PI3K/mTOR and JAK or ABL inhibition in murine xenograft models of Ph-like acute lymphoblastic leukemia. (2017) (123)
- Advances in the management and understanding of autoimmune lymphoproliferative syndrome (ALPS) (2010) (121)
- Optimizing Chimeric Antigen Receptor T-Cell Therapy for Adults With Acute Lymphoblastic Leukemia. (2019) (113)
- CAR T-cell therapy is effective for CD19-dim B-lymphoblastic leukemia but is impacted by prior blinatumomab therapy. (2019) (110)
- Tandem high-dose therapy in rapid sequence for children with high-risk neuroblastoma. (2000) (110)
- Mammalian target of rapamycin inhibitors and their potential role in therapy in leukaemia and other haematological malignancies (2009) (110)
- Monocyte lineage-derived IL-6 does not affect chimeric antigen receptor T-cell function. (2017) (109)
- Engineered T cells for cancer therapy (2014) (106)
- Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune effector cell-related adverse events (2020) (106)
- Targeting the PI3K/AKT/mTOR Signaling Axis in Children with Hematologic Malignancies (2012) (104)
- Safety and efficacy of allogeneic PBSC collection in normal pediatric donors: The Pediatric Blood and Marrow Transplant Consortium Experience (PBMTC) 1996–2003 (2005) (103)
- The addition of sirolimus to tacrolimus/methotrexate GVHD prophylaxis in children with ALL: a phase 3 Children's Oncology Group/Pediatric Blood and Marrow Transplant Consortium trial. (2014) (103)
- Regimen-specific effects of RNA-modified chimeric antigen receptor T cells in mice with advanced leukemia. (2013) (102)
- Eradication of B-ALL using chimeric antigen receptor-expressing T cells targeting the TSLPR oncoprotein. (2015) (101)
- Intracellular targeting of antigens internalized by membrane immunoglobulin in B lymphocytes (1995) (98)
- Phase I study of temsirolimus in pediatric patients with recurrent/refractory solid tumors. (2011) (93)
- Updated Analysis of the Efficacy and Safety of Tisagenlecleucel in Pediatric and Young Adult Patients with Relapsed/Refractory (r/r) Acute Lymphoblastic Leukemia (2018) (93)
- Relation of clinical culture method to T-cell memory status and efficacy in xenograft models of adoptive immunotherapy. (2014) (92)
- Checkpoint Inhibitors Augment CD19-Directed Chimeric Antigen Receptor (CAR) T Cell Therapy in Relapsed B-Cell Acute Lymphoblastic Leukemia (2018) (89)
- The angiogenesis inhibitor tnp-470 effectively inhibits human neuroblastoma xenograft growth, especially in the setting of subclinical disease. (2001) (89)
- Identifying autoimmune lymphoproliferative syndrome in children with Evans syndrome: a multi-institutional study. (2010) (85)
- Systemic and local immunity following adoptive transfer of NY-ESO-1 SPEAR T cells in synovial sarcoma (2019) (85)
- Reduced-intensity allogeneic transplantation in pediatric patients ineligible for myeloablative therapy: results of the Pediatric Blood and Marrow Transplant Consortium Study ONC0313. (2009) (85)
- Final results from a defibrotide treatment‐IND study for patients with hepatic veno‐occlusive disease/sinusoidal obstruction syndrome (2018) (83)
- Rapamycin improves lymphoproliferative disease in murine autoimmune lymphoproliferative syndrome (ALPS). (2006) (81)
- Clinical Utilization of Chimeric Antigen Receptor T Cells in B Cell Acute Lymphoblastic Leukemia: An Expert Opinion from the European Society for Blood and Marrow Transplantation and the American Society for Blood and Marrow Transplantation. (2019) (80)
- Toxicity management after chimeric antigen receptor T cell therapy: one size does not fit 'ALL' (2018) (79)
- Targeting Notch signaling in autoimmune and lymphoproliferative disease. (2008) (77)
- Thymic stromal-derived lymphopoietin induces proliferation of pre-B leukemia and antagonizes mTOR inhibitors, suggesting a role for interleukin-7Ralpha signaling. (2007) (75)
- Tisagenlecleucel Model‐Based Cellular Kinetic Analysis of Chimeric Antigen Receptor–T Cells (2019) (75)
- Clinical utilization of Chimeric Antigen Receptor T-cells (CAR-T) in B-cell acute lymphoblastic leukemia (ALL)–an expert opinion from the European Society for Blood and Marrow Transplantation (EBMT) and the American Society for Blood and Marrow Transplantation (ASBMT) (2019) (74)
- Analysis of a Global Registration Trial of the Efficacy and Safety of CTL019 in Pediatric and Young Adults with Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) (2016) (73)
- The effect of pembrolizumab in combination with CD19-targeted chimeric antigen receptor (CAR) T cells in relapsed acute lymphoblastic leukemia (ALL). (2017) (73)
- Randomized, Phase II Dose Optimization Study of Chimeric Antigen Receptor Modified T Cells Directed Against CD19 (CTL019) in Patients with Relapsed, Refractory CLL (2013) (73)
- Stem cell transplantation for neuroblastoma (2008) (70)
- Risk-Adapted Preemptive Tocilizumab to Prevent Severe Cytokine Release Syndrome After CTL019 for Pediatric B-Cell Acute Lymphoblastic Leukemia: A Prospective Clinical Trial. (2021) (69)
- Repeated loss of target surface antigen after immunotherapy in primary mediastinal large B cell lymphoma (2017) (69)
- Global Registration Trial of Efficacy and Safety of CTL019 in Pediatric and Young Adult Patients with Relapsed/Refractory (R/R) Acute Lymphoblastic Leukemia (ALL): Update to the Interim Analysis (2017) (69)
- Signaling-defective mutants of the B lymphocyte antigen receptor fail to associate with Ig-alpha and Ig-beta/gamma. (1993) (68)
- Immunosurveillance and survivin-specific T-cell immunity in children with high-risk neuroblastoma. (2006) (67)
- Late effects in survivors of tandem peripheral blood stem cell transplant for high‐risk neuroblastoma (2008) (67)
- Neurotoxicity after CTL019 in a pediatric and young adult cohort (2018) (67)
- Efficacy and Safety of CTL019 in the First US Phase II Multicenter Trial in Pediatric Relapsed/Refractory Acute Lymphoblastic Leukemia: Results of an Interim Analysis (2016) (66)
- A novel antibody-TCR (AbTCR) platform combines Fab-based antigen recognition with gamma/delta-TCR signaling to facilitate T-cell cytotoxicity with low cytokine release (2018) (65)
- More precisely defining risk peri-HCT in pediatric ALL: pre- vs post-MRD measures, serial positivity, and risk modeling. (2019) (65)
- A phase III randomized clinical trial (RCT) of tandem myeloablative autologous stem cell transplant (ASCT) using peripheral blood stem cell (PBSC) as consolidation therapy for high-risk neuroblastoma (HR-NB): A Children's Oncology Group (COG) study. (2016) (65)
- Chimeric antigen receptor T-cell therapy for ALL. (2014) (64)
- CAR T Cell Therapy in Acute Lymphoblastic Leukemia and Potential for Chronic Lymphocytic Leukemia (2016) (64)
- Efficacy of Humanized CD19-Targeted Chimeric Antigen Receptor (CAR)-Modified T Cells in Children and Young Adults with Relapsed/Refractory Acute Lymphoblastic Leukemia (2016) (64)
- Aggressive surgical therapy and radiotherapy for patients with high-risk neuroblastoma treated with rapid sequence tandem transplant. (2005) (62)
- Nature of Tumor Control by Permanently and Transiently Modified GD2 Chimeric Antigen Receptor T Cells in Xenograft Models of Neuroblastoma (2014) (60)
- Purification of mRNA Encoding Chimeric Antigen Receptor Is Critical for Generation of a Robust T-Cell Response (2019) (59)
- CD19-targeting CAR T cell immunotherapy outcomes correlate with genomic modification by vector integration. (2019) (58)
- Earlier defibrotide initiation post‐diagnosis of veno‐occlusive disease/sinusoidal obstruction syndrome improves Day +100 survival following haematopoietic stem cell transplantation (2017) (57)
- Autologous and allogeneic cellular therapies for high-risk pediatric solid tumors. (2010) (56)
- Increased phosphatidylinositol metabolism is an important but not an obligatory early event in B lymphocyte activation. (1985) (55)
- TNF-receptor inhibitor therapy for the treatment of children with idiopathic pneumonia syndrome. A joint Pediatric Blood and Marrow Transplant Consortium and Children's Oncology Group Study (ASCT0521). (2015) (55)
- Noninvasive bioluminescent imaging of primary patient acute lymphoblastic leukemia: a strategy for preclinical modeling. (2011) (55)
- Endogenous knockdown of survivin improves chemotherapeutic response in ALL models (2012) (53)
- Randomized trial of hydroxychloroquine for newly diagnosed chronic graft-versus-host disease in children: a Children's Oncology Group study. (2012) (53)
- Molecular mechanisms that control expression of the B lymphocyte antigen receptor complex (1995) (52)
- iNKT Cell Cytotoxic Responses Control T-Lymphoma Growth In Vitro and In Vivo (2013) (50)
- A prospective study of G-CSF primed bone marrow as a stem-cell source for allogeneic bone marrow transplantation in children: a Pediatric Blood and Marrow Transplant Consortium (PBMTC) study. (2007) (48)
- In vivo control of acute lymphoblastic leukemia by immunostimulatory CpG oligonucleotides. (2006) (47)
- Defibrotide for the treatment of hepatic veno-occlusive disease in children after hematopoietic stem cell transplantation (2012) (45)
- Thrombopoietic Activity of Recombinant Human Interleukin 11 (rHuIL‐11) in Normal and Myelosuppressed Nonhuman Primates (1996) (45)
- Antigen-independent activation enhances the efficacy of 4-1BB-costimulated CD22 CAR T cells (2021) (45)
- Integrative bulk and single-cell profiling of pre-manufacture T-cell populations reveals factors mediating long-term persistence of CAR T-cell therapy. (2021) (44)
- Refractory Cytokine Release Syndrome in Recipients of Chimeric Antigen Receptor (CAR) T Cells (2014) (44)
- CD19 Alterations Emerging after CD19-Directed Immunotherapy Cause Retention of the Misfolded Protein in the Endoplasmic Reticulum (2018) (44)
- Patient-reported quality of life after tisagenlecleucel infusion in children and young adults with relapsed or refractory B-cell acute lymphoblastic leukaemia: a global, single-arm, phase 2 trial. (2019) (44)
- Use of G‐CSF in Matched Sibling Donor Pediatric Allogeneic Transplantation: A Consensus Statement from the Children's Oncology Group (COG) Transplant Discipline Committee and Pediatric Blood and Marrow Transplant Consortium (PBMTC) Executive Committee (2006) (44)
- Nonviral RNA chimeric antigen receptor-modified T cells in patients with Hodgkin lymphoma. (2018) (44)
- Defibrotide for Patients with Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome: Interim Results from a Treatment IND Study. (2017) (43)
- Retention of CD19 intron 2 contributes to CART-19 resistance in leukemias with subclonal frameshift mutations in CD19 (2019) (43)
- Optimizing chimeric antigen receptor (CAR) T cell therapy for adult patients with relapsed or refractory (r/r) acute lymphoblastic leukemia (ALL). (2016) (43)
- The MAGIC algorithm probability is a validated response biomarker of treatment of acute graft-versus-host disease. (2019) (43)
- Humanized CD19-Targeted Chimeric Antigen Receptor (CAR) T Cells in CAR-Naive and CAR-Exposed Children and Young Adults With Relapsed or Refractory Acute Lymphoblastic Leukemia (2021) (42)
- Dual CD 19 and CD 123 targeting prevents antigen-loss relapses after CD 19-directed immunotherapies (2019) (41)
- Improved anti-leukemia activities of adoptively transferred T cells expressing bispecific T-cell engager in mice (2016) (40)
- Rapid-sequence tandem transplant for children with high-risk neuroblastoma. (2000) (40)
- Blinatumomab Nonresponse and High-Disease Burden Are Associated With Inferior Outcomes After CD19-CAR for B-ALL (2021) (40)
- A Pilot Study of Tandem High Dose Chemotherapy with Stem Cell Rescue as Consolidation for High Risk Neuroblastoma: Children’s Oncology Group study ANBL00P1 (2012) (39)
- Long-term protection from syngeneic acute lymphoblastic leukemia by CpG ODN-mediated stimulation of innate and adaptive immune responses. (2009) (39)
- Efficient Trafficking of Chimeric Antigen Receptor (CAR)-Modified T Cells to CSF and Induction of Durable CNS Remissions in Children with CNS/Combined Relapsed/Refractory ALL (2015) (39)
- Novel molecular and cellular therapeutic targets in acute lymphoblastic leukemia and lymphoproliferative disease (2008) (38)
- Adoptive Transfer of Autologous T Cells Improves T-cell Repertoire Diversity and Long-term B-cell Function in Pediatric Patients with Neuroblastoma (2012) (38)
- Chimeric Antigen Receptor T Cell Therapy During the COVID-19 Pandemic (2020) (36)
- T cells targeting NY-ESO-1 demonstrate efficacy against disseminated neuroblastoma (2016) (36)
- CAR-T cells: Early successes in blood cancer and challenges in solid tumors (2020) (35)
- Higher Reported Lung Dose Received During Total Body Irradiation for Allogeneic Hematopoietic Stem Cell Transplantation in Children With Acute Lymphoblastic Leukemia Is Associated With Inferior Survival: A Report from the Children's Oncology Group. (2019) (35)
- Early and late extensive chronic graft-versus-host disease in children is characterized by different Th1/Th2 cytokine profiles: findings of the Children's Oncology Group Study ASCT0031. (2011) (35)
- Chimeric Antigen Receptor Modified T Cells Directed Against CD19 (CTL019 cells) Have Long-Term Persistence and Induce Durable Responses In Relapsed, Refractory CLL (2013) (34)
- Randomized, phase II dose optimization study of chimeric antigen receptor (CAR) modified T cells directed against CD19 in patients (pts) with relapsed, refractory (R/R) CLL. (2016) (33)
- Toxicities of busulfan/melphalan versus carboplatin/etoposide/melphalan for high-dose chemotherapy with stem cell rescue for high-risk neuroblastoma (2016) (32)
- Single agent and synergistic combinatorial efficacy of first-in-class small molecule imipridone ONC201 in hematological malignancies (2018) (31)
- Targeting JAK 1 / 2 and mTOR in Murine Xenograft Models of Ph-like Acute Lymphoblastic Leukemia ( ALL ) (2012) (30)
- Interferon-γ–Dependent Infiltration of Human T Cells into Neuroblastoma Tumors In vivo (2009) (29)
- Next-Generation Sequencing of Minimal Residual Disease for Predicting Relapse after Tisagenlecleucel in Children and Young Adults with Acute Lymphoblastic Leukemia (2021) (29)
- Tisagenlecleucel Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory Children and Young Adults with Acute Lymphoblastic Leukemia (ALL): Real World Experience from the Center for International Blood and Marrow Transplant Research (CIBMTR) and Cellular Therapy (CT) Registry (2019) (29)
- Safety and Efficacy of CTX001 in Patients with Transfusion-Dependent β-Thalassemia and Sickle Cell Disease: Early Results from the Climb THAL-111 and Climb SCD-121 Studies of Autologous CRISPR-CAS9-Modified CD34+ Hematopoietic Stem and Progenitor Cells (2020) (28)
- Unrelated donor bone marrow transplantation for children with severe aplastic anemia: minimal GVHD and durable engraftment with partial T cell depletion (2005) (28)
- Beyond the storm — subacute toxicities and late effects in children receiving CAR T cells (2021) (27)
- ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION FOR NEUROBLASTOMA: THE CIBMTR EXPERIENCE (2013) (27)
- CD19-targeted chimeric antigen receptor T-cell therapy for CNS relapsed or refractory acute lymphocytic leukaemia: a post-hoc analysis of pooled data from five clinical trials. (2021) (27)
- A Phase I/II study of the safety and efficacy of the addition of sirolimus to tacrolimus/methotrexate graft versus host disease prophylaxis after allogeneic haematopoietic cell transplantation in paediatric acute lymphoblastic leukaemia (ALL) (2009) (26)
- Feasibility of a tandem autologous peripheral blood stem cell transplant regimen for high risk neuroblastoma in a cooperative group setting: A Pediatric Oncology Group study: A Report from the Children's Oncology Group (2012) (26)
- Chimeric Antigen Receptor T Cells Directed Against CD19 Induce Durable Responses and Transient Cytokine Release Syndrome in Relapsed, Refractory CLL and ALL (2012) (26)
- Lingering effects of chemotherapy on mature T cells impair proliferation. (2020) (26)
- Outcomes of transplantation with partial T-cell depletion of matched or mismatched unrelated or partially matched related donor bone marrow in children and adolescents with leukemias (2005) (25)
- Efficacy of humanized CD19-targeted chimeric antigen receptor (CAR)-modified T cells in children with relapsed ALL. (2016) (25)
- Defibrotide (DF) in the Treatment of Severe Hepatic Veno-Occlusive Disease (VOD) with Multi-Organ Failure (MOF) Following Stem Cell Transplantation (SCT): Results of a Phase 3 Study Utilizing a Historical Control. (2009) (25)
- The phosphatidylinositol response is an early event in the physiologically relevant activation of antigen-specific B lymphocytes. (1987) (25)
- Efficacy and Safety of Humanized Chimeric Antigen Receptor (CAR)-Modified T Cells Targeting CD19 in Children with Relapsed/Refractory ALL (2015) (25)
- CAR T Cell Therapy During the COVID-19 Pandemic. (2020) (24)
- Cutting Edge: Lymphoproliferation Caused by Fas Deficiency Is Dependent on the Transcription Factor Eomesodermin (2010) (24)
- Long-Term Functional Persistence, B Cell Aplasia and Anti-Leukemia Efficacy In Refractory B Cell Malignancies Following T Cell Immunotherapy Using CAR-Redirected T Cells Targeting CD19 (2013) (24)
- Disease burden and conditioning regimens in ASCT1221, a randomized phase II trial in children with juvenile myelomonocytic leukemia: A Children's Oncology Group study (2018) (24)
- Tacrolimus/Sirolimus Vs. Tacrolimus/Methotrexate for Graft-Vs.-Host Disease Prophylaxis After HLA-Matched, Related Donor Hematopoietic Stem Cell Transplantation: Results of Blood and Marrow Transplant Clinical Trials Network Trial 0402 (2012) (24)
- Defibrotide for the treatment of hepatic veno‐occlusive disease/sinusoidal obstruction syndrome following nontransplant‐associated chemotherapy: Final results from a post hoc analysis of data from an expanded‐access program (2018) (24)
- Interleukin 6 Is Not Made By Chimeric Antigen Receptor T Cells and Does Not Impact Their Function (2016) (23)
- Beginning the CAR T cell therapy revolution in the US and EU. (2018) (23)
- The ligand-induced membrane IgM association with the cytoskeletal matrix of B cells is not mediated through the Ig alpha beta heterodimer. (1995) (23)
- T Cells Engineered with a Chimeric Antigen Receptor (CAR) Targeting CD19 (CTL019) Have Long Term Persistence and Induce Durable Remissions in Children with Relapsed, Refractory ALL (2014) (23)
- Defibrotide for the treatment of hepatic veno-occlusive disease/sinusoidal obstruction syndrome with multiorgan failure. (2017) (22)
- Management of radiation-induced tracheocutaneous tissue defects by transplantation of an ear cartilage graft and deltopectoral flap. (2006) (22)
- Inhibition of tumor growth in a human neuroblastoma xenograft model with TNP-470. (2000) (22)
- Durable Remissions with Humanized CD19-Targeted Chimeric Antigen Receptor (CAR)-Modified T Cells in CAR-Naive and CAR-Exposed Children and Young Adults with Relapsed/Refractory Acute Lymphoblastic Leukemia (2017) (22)
- Single-cell antigen-specific landscape of CAR T infusion product identifies determinants of CD19-positive relapse in patients with ALL (2022) (21)
- Collection, storage, and infusion of stem cells in children with high‐risk neuroblastoma: Saving for a rainy day (2006) (20)
- Diagnostic biomarkers to differentiate sepsis from cytokine release syndrome in critically ill children. (2020) (20)
- Advances in T-cell therapy for ALL. (2014) (20)
- Early events in B-cell activation: anti-Lyb2, but not BSF-1, induces a phosphatidylinositol response in murine B cells. (1987) (20)
- Prospective Evaluation of Radiation Dose Escalation in Patients With High-Risk Neuroblastoma and Gross Residual Disease After Surgery: A Report From the Children's Oncology Group ANBL0532 Study. (2020) (19)
- Open label, non-randomized, multi-cohort pilot study of genetically engineered NY-ESO-1 specific NY-ESO-1c259t in HLA-A2+ patients with synovial sarcoma (NCT01343043). (2017) (19)
- Single-cell multiomics dissection of basal and antigen-specific activation states of CD19-targeted CAR T cells (2021) (19)
- Role of μ Heavy Chain in B Cell Development. I. Blocked B Cell Maturation But Complete Allelic Exclusion in the Absence of Igα/β (1998) (19)
- Subcutaneous immunoglobulin replacement following CD19‐specific chimeric antigen receptor T‐cell therapy for B‐cell acute lymphoblastic leukemia in pediatric patients (2019) (19)
- Practical guidelines for monitoring and management of coagulopathy following tisagenlecleucel CAR T-cell therapy. (2021) (18)
- A randomized phase III trial of myeloablative autologous peripheral blood stem cell (PBSC) transplant (ASCT) for high-risk neuroblastoma (HR-NB) employing immunomagnetic purged (P) versus unpurged (UP) PBSC: A Children’s Oncology Group study (2008) (18)
- Tisagenlecleucel for the treatment of B-cell acute lymphoblastic leukemia (2018) (18)
- Cytokine Release Syndrome after Haploidentical Stem Cell Transplantation. (2016) (17)
- CD19-Redirected Chimeric Antigen Receptor T (CART19) Cells Induce a Cytokine Release Syndrome (CRS) and Induction of Treatable Macrophage Activation Syndrome (MAS) That Can Be Managed by the IL-6 Antagonist Tocilizumab (toc). (2012) (17)
- CAR T cell viability release testing and clinical outcomes: is there a lower limit? (2019) (16)
- Cars in Leukemia: Relapse with Antigen-Negative Leukemia Originating from a Single B Cell Expressing the Leukemia-Targeting CAR (2016) (16)
- Pooled safety analysis of tisagenlecleucel in children and young adults with B cell acute lymphoblastic leukemia (2021) (16)
- Effect of chimeric antigen receptor-modified T (CAR-T) cells on responses in children with non-CNS extramedullary relapse of CD19+ acute lymphoblastic leukemia (ALL). (2017) (16)
- Veno-occlusive disease after high-dose busulfan–melphalan in neuroblastoma (2018) (16)
- Adoptive cellular therapy. (2011) (15)
- Impact of high-risk cytogenetics on outcomes for children and young adults receiving CD19-directed CAR T cell therapy. (2021) (15)
- Preinfusion factors impacting relapse immunophenotype following CD19 CAR T cells (2022) (15)
- False-positive results with select HIV-1 NAT methods following lentivirus-based tisagenlecleucel therapy. (2018) (14)
- 73: Low rates of toxicity and long-term responses after bu/flu/ATG RIC allogeneic transplantation in very high risk pediatric patients ineligible for myelablative therapy: A Pediatric Blood and Marrow Transplant Consortium Study (2007) (14)
- Molecular Detection of Minimal Residual Disease Precedes Morphological Relapse and Could be Used to Identify Relapse in Pediatric and Young Adult B-Cell Acute Lymphoblastic Leukemia Patients Treated with Tisagenlecleucel (2018) (14)
- Tisagenlecleucel for the Treatment of Pediatric and Young Adult Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia: Updated Analysis of the ELIANA Clinical Trial (2019) (14)
- Real World Experience of Tisagenlecleucel Chimeric Antigen Receptor (CAR) T-Cells Targeting CD19 in Patients with Acute Lymphoblastic Leukemia (ALL) and Diffuse Large B-Cell Lymphoma (DLBCL) Using the Center for International Blood and Marrow Transplant Research (CIBMTR) Cellular Therapy (CT) Regist (2019) (14)
- Will allogeneic CAR T cells for CD19+ malignancies take autologous CAR T cells ‘off the shelf’? (2021) (14)
- Neuroblastoma: issues in transplantation. (2012) (14)
- Absolute lymphocyte count proliferation kinetics after CAR T-cell infusion impact response and relapse. (2021) (14)
- Statins are active in acute lymphoblastic leukaemia (ALL): a therapy that may treat ALL and prevent avascular necrosis (2011) (14)
- IFN‐γ directly inhibits murine B‐cell precursor leukemia‐initiating cell proliferation early in life (2017) (13)
- Cytosine base editing enables quadruple-edited allogeneic CART cells for T-ALL (2022) (13)
- Inhibition of precursor B cell malignancy progression by toll-like receptor ligand-induced immune responses (2016) (12)
- Early administration of tocilizumab (Toci) for the prevention of grade 4 cytokine release syndrome (CRS) after CD19-directed CAR T-cell therapy (CTL019) (2019) (12)
- CD19-targeted chimeric antigen receptor (CAR) T cells in CNS relapsed acute lymphoblastic leukemia (ALL). (2020) (12)
- Risk-Adapted Preemptive Tocilizumab Decreases Severe Cytokine Release Syndrome (CRS) after CTL019 CD19-Targeted Chimeric Antigen Receptor (CAR) T-Cell Therapy for Pediatric B-Cell Acute Lymphoblastic Leukemia (B-ALL) (2020) (12)
- Anti-CD123 Chimeric Antigen Receptor T Cells (CART-123) Provide A Novel Myeloablative Conditioning Regimen That Eradicates Human Acute Myeloid Leukemia In Preclinical Models (2013) (12)
- Efficient Termination of CD123-Redirected Chimeric Antigen Receptor T Cells for Acute Myeloid Leukemia to Mitigate Toxicity (2015) (12)
- Unrelated donor or partially matched related donor peripheral stem cell transplant with CD34+ selection and CD3+ addback for pediatric patients with leukemias (2006) (11)
- S112: TISAGENLECLEUCEL IN PEDIATRIC AND YOUNG ADULT PATIENTS (PTS) WITH RELAPSED/REFRACTORY (R/R) B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA (B-ALL): FINAL ANALYSES FROM THE ELIANA STUDY (2022) (11)
- Defibrotide (DF) in the Treatment of Hepatic Veno-Occlusive Disease (VOD) in Stem Cell Transplant (SCT) and Non-SCT Patients (Pts): Early Intervention Improves Outcome - Updated Results of a Treatment IND Expanded Access Protocol (2011) (11)
- Dissecting the Tumor–Immune Landscape in Chimeric Antigen Receptor T-cell Therapy: Key Challenges and Opportunities for a Systems Immunology Approach (2020) (11)
- Combination of Anti-CD123 and Anti-CD19 Chimeric Antigen Receptor T Cells for the Treatment and Prevention of Antigen-Loss Relapses Occurring after CD19-Targeted Immunotherapies (2015) (10)
- Will post-transplantation cell therapies for pediatric patients become standard of care? (2015) (10)
- Roadblocks to success for RNA CARs in solid tumors (2014) (10)
- Allogeneic marrow transplantation in children with acute leukemia: careful comparison with chemotherapy alternatives required (2010) (10)
- 31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one (2016) (10)
- Tisagenlecleucel in pediatric and young adult patients with Down syndrome-associated relapsed/refractory acute lymphoblastic leukemia (2022) (9)
- Humanized chimeric antigen receptor (CAR)-modified T cells targeting CD19 induce remissions in children and young adults with relapsed/refractory lymphoblastic leukemia/lymphoma (2017) (9)
- Children's Oncology Group's 2013 blueprint for research: Stem cell transplantation (2013) (9)
- Challenges and opportunities for international cooperative studies in pediatric hematopoeitic cell transplantation: priorities of the Westhafen Intercontinental Group. (2013) (9)
- Series ACUTE LYMPHOBLASTIC LEUKEMIA CD 19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia (2016) (9)
- A Phase I Trial of Sirolimus (Rapamycin) in Pediatric Patients with Relapsed/Refractory Leukemia. (2007) (9)
- Sirolimus pharmacokinetics in early postmyeloablative pediatric blood and marrow transplantation. (2013) (9)
- Outcomes after HLA-Matched Sibling Transplants or Chemotherapy in Children with Acute Lymphoblastic Leukemia in a Second Remission after an Isolated Central Nervous System Relapse. (2006) (9)
- Meta-Analysis of Defibrotide (DF) In the Treatment of Severe Hepatic Veno-Occlusive Disease (VOD) with Multi-Organ Failure (MOF) with Comparison to a Historical Control (HC). (2010) (9)
- Cytoplasmic μ Heavy Chain Confers Sensitivity to Dexamethasone-induced Apoptosis in Early B-lineage Acute Lymphoblastic Leukemia (2002) (9)
- CAR-T in the clinic: drive with care (2018) (9)
- Genetically engineered NY-ESO-1 specific T cells in HLA-A201+ patients with advanced cancers. (2015) (8)
- A safety and feasibility trial of 131I‐MIBG in newly diagnosed high‐risk neuroblastoma: A Children's Oncology Group study (2021) (8)
- Evaluation of elafin as a prognostic biomarker in acute graft-versus-host disease. (2021) (8)
- Single Chain Variable Fragment Linker Length Regulates CAR Biology and T Cell Efficacy (2019) (8)
- Correction to: Grading of cytokine release syndrome associated with the CAR T cell therapy tisagenlecleucel (2018) (8)
- Pooled analysis of Day 100 survival for defibrotide‐treated patients with hepatic veno‐occlusive disease/sinusoidal obstruction syndrome and ventilator or dialysis dependence following haematopoietic cell transplantation (2020) (7)
- CD19-Directed CAR T-Cell (CTL019) Product Viability and Clinical Outcomes in Non-Hodgkin Lymphomas and B-Cell Acute Lymphoblastic Leukemia (2018) (7)
- Real-World Outcomes for Pediatric and Young Adult Patients with Relapsed or Refractory (R/R) B-Cell Acute Lymphoblastic Leukemia (ALL) Treated with Tisagenlecleucel: Update from the Center for International Blood and Marrow Transplant Research (CIBMTR) Registry (2021) (7)
- Novel Chimeric Antigen Receptor T Cells for the Treatment of CD19-Negative Relapses Occurring after CD19-Targeted Immunotherapies (2014) (7)
- Cytokine Release Syndrome (CRS) after Chimeric Antigen Receptor (CAR) T Cell Therapy for Relapsed/Refractory (R/R) CLL (2014) (7)
- Phase‐1 study of siplizumab in the treatment of pediatric patients with at least grade II newly diagnosed acute graft‐versus‐host disease (2010) (7)
- KMT2A Rearrangements Are Associated with Lineage Switch Following CD19 Targeting CAR T-Cell Therapy (2021) (7)
- Defibrotide (DF) In the Treatment of Severe Hepatic Veno-Occlusive Disease (VOD) with Multi-Organ Failure (MOF): Results of a Treatment IND Expanded Access Protocol (2010) (7)
- High Vs. Low-Intensity Bridging Chemotherapy in Children with Acute Lymphoblastic Leukemia Awaiting Chimeric Antigen Receptor T-Cell Therapy: A Population-Based Study from Ontario, Canada (2018) (7)
- Tisagenlecleucel immunogenicity in relapsed/refractory acute lymphoblastic leukemia and diffuse large B-cell lymphoma (2021) (7)
- Efficacy and safety of tisagenlecleucel in Japanese pediatric and young adult patients with relapsed/refractory B cell acute lymphoblastic leukemia (2019) (6)
- TNF receptor inhibitor therapy for the treatment of children with idiopathic pneumonia syndrome (IPS): A joint Pediatric Blood and Marrow Transplant Consortium (PBMTC) and Children’s Oncology Group (COG) study (ASCT0521) (2015) (6)
- Timing of Initiation of Defibrotide Post-Diagnosis of Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome Post-Hematopoietic Stem Cell Transplantation: Exploratory Age-Group Analysis from an Expanded Access Study (2016) (6)
- CTL019 Clinical Pharmacology and Biopharmaceutics in Pediatric Patients with Relapsed or Refractory (R/R) Acute Lymphoblastic Leukemia (ALL) (2017) (6)
- Biomarkers Accurately Predict Cytokine Release Syndrome (CRS) after Chimeric Antigen Receptor (CAR) T Cell Therapy for Acute Lymphoblastic Leukemia (ALL) (2015) (6)
- Striking Predictive Power For Relapse and Decreased Survival Associated With Detectable Minimal Residual Disease by IGH VDJ Deep Sequencing Of Bone Marrow Pre- and Post-Allogeneic Transplant In Children With B-Lineage ALL: A Subanalysis Of The COG ASCT0431/PBMTC ONC051 Study (2013) (6)
- In Vivo Efficacy of PI3K Pathway Signaling Inhibition for Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia (2013) (6)
- Cytogenetic Characteristics and Outcomes of Patients Receiving CTL019 CAR T Cell Therapy (2019) (6)
- Three-Year Update of Tisagenlecleucel in Pediatric and Young Adult Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia in the ELIANA Trial (2022) (6)
- Role of the BCR complex in B cell development, activation, and leukemic transformation (2003) (6)
- CTL019 Model-Based Cellular Kinetic Analysis of Chimeric Antigen Receptor (CAR) T Cells to Characterize the Impact of Tocilizumab on Expansion and to Identify Correlates of Cytokine Release Syndrome Severity (2017) (6)
- A Prospective Study of G-CSF Primed Bone Marrow from Pediatric Donors as a Stem Cell Source for Allogeneic Bone Marrow Transplant: A Pediatric Blood and Marrow Transplant Consortium (PBMTC) Study. (2005) (5)
- Targeting mTOR and JAK2 in Xenograft Models of CRLF2-Overexpressing Acute Lymphoblastic Leukemia (ALL) (2011) (5)
- Inhibition of lymphocyte proliferation by detergent-solubilized mouse liver membranes (1985) (5)
- The Relationship of Acute Gvhd and Pre- and Post-Transplant Flow-MRD to the Incidence and Timing of Relapse in Children Undergoing Allogeneic Transplantation for High Risk ALL: Defining a Target Population and Window for Immunological Intervention to Prevent Relapse (2012) (5)
- Treatment of leukemia antigen-loss relapses occurring after CD19-targeted immunotherapies by combination of anti-CD123 and anti-CD19 chimeric antigen receptor T cells (2015) (5)
- Correlation of pre-CAR CD19 expression with responses and relapses after CAR T cell therapy. (2018) (5)
- Outcomes after Reinfusion of CD19-Specific Chimeric Antigen Receptor (CAR)-Modified T Cells in Children and Young Adults with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia (2021) (5)
- Clinical Utilization of Chimeric Antigen Receptor T Cells in B Cell Acute Lymphoblastic Leukemia: An Expert Opinion from the European Society for Blood and Marrow Transplantation and the American Society for Transplantation and Cellular Therapy (2021) (5)
- Immunotherapy for pediatric cancer. (2008) (5)
- Role of mu heavy chain in B cell development. I. Blocked B cell maturation but complete allelic exclusion in the absence of Ig alpha/beta. (1998) (5)
- Immunogenicity of tisagenlecleucel in relapsed/ refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL) and diffuse large B-cell lymphoma (DLBCL) patients. (2018) (5)
- Anti-CD13 antibodies in children with extensive chronic graft-versus-host disease and their relation to soluble CD13 after allogeneic blood and marrow transplantation from a Children's Oncology Groups Study, ASCT0031 (2010) (5)
- Abstract CT077: Potential utility of minimal residual disease (MRD) to identify relapse in pediatric and young adult (AYA) B-cell acute lymphoblastic leukemia (B-ALL) patients treated with tisagenlecleucel (2019) (5)
- Role of Radiotherapy Dose-Escalation for High-Risk Neuroblastoma with Post-Surgical Primary Site Gross Residual Disease: A Report from the COG ANBL0532 Study (2019) (5)
- Acute Kidney Injury after Chimeric Antigen Receptor T-Cell Therapy for Pediatric Acute Lymphoblastic Leukemia (2019) (5)
- Immune Reconstitution Following TCRαβ/CD19-Depleted Hematopoietic Cell Transplantation for Hematologic Malignancy in Pediatric Patients. (2021) (5)
- A Phase 3, Randomized, Adaptive Study of Defibrotide (DF) Vs Best Supportive Care (BSC) for the Prevention of Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome (VOD/SOS) in Patients (pts) Undergoing Hematopoietic Cell Transplantation (HCT): Preliminary Results (2021) (4)
- Management of Coagulopathy Associated with CTL019 CAR T-Cell Therapy (2017) (4)
- Defibrotide for the Treatment of Severe Hepatic Veno-Occlusive Disease: An Analysis of Clinical Benefit As Determined By Number Needed to Treat (NNT) to Achieve Complete Response and to Improve Survival (2014) (4)
- Abstract PR06: T cells engineered with a chimeric antigen receptor (CAR) targeting CD19 (CTL019) produce complete responses and long-term persistence without GVHD in children with relapsed, refractory ALL (2014) (4)
- Early Initiation of Defibrotide in Patients with Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome Following Hematopoietic Stem Cell Transplantation Improves Day +100 Survival (2015) (4)
- Clinical Efficacy of Anti-CD22 Chimeric Antigen Receptor T Cells for B-Cell Acute Lymphoblastic Leukemia Is Correlated with the Length of the Scfv Linker and Can be Predicted Using Xenograft Models (2017) (4)
- Recent developments with defibrotide for the treatment of hepatic veno-occlusive disease/sinusoidal obstruction syndrome (2019) (4)
- CD3+/CD19+ Depleted Matched and Mismatched Unrelated Donor Hematopoietic Stem Cell Transplant with Targeted T Cell Addback Is Associated with Excellent Outcomes in Pediatric Patients with Nonmalignant Hematologic Disorders. (2019) (4)
- HESTER: A Phase II Study Evaluating Efficacy and Safety of Tisagenlecleucel Reinfusion in Pediatric and Young Adult Patients with Acute Lymphoblastic Leukemia Experiencing Loss of B-Cell Aplasia (2020) (4)
- Generation of a multi-antigen-directed immune response for durable control of acute lymphoblastic leukemia (2018) (4)
- Myeloablative busulfan/melphalan (BuMel) consolidation following induction chemotherapy for patients with high-risk neuroblastoma: A Children’s Oncology Group (COG) study. (2016) (4)
- Association of higher lung dose received during total body irradiation for allogeneic hematopoetic stem cell transplantation in children with acute lymphoblastic leukemia with inferior progression-free and overall survival: A report from the Children’s Oncology Group. (2015) (4)
- Cellular Kinetics of Chimeric Antigen Receptor T Cells (CTL019) in Patients with Relapsed/Refractory CD19+ Leukemia (2016) (4)
- Analysis of Time to Complete Response after Defibrotide Initiation in Patients with Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome after Hematopoietic Cell Transplantation (2020) (4)
- Competitive TNF Inhibitor (ETANERCEPT) for the Treatment of Idiopathic Pneumonia Syndrome (IPS) Following Allogeneic Stem Cell Transplantation (SCT). A Joint Pediatric Blood and Marrow Transplant Consortium (PBMTC) and Childrens Oncology Group (COG) Study (2013) (4)
- Biomarker Profiling Differentiates Sepsis from Cytokine Release Syndrome in Chimeric Antigen Receptor T-Cell Therapy for Acute Lymphoblastic Leukemia (ALL) (2016) (4)
- Updated Results from the Ongoing US Treatment IND Study Using Defibrotide for Patients with Hepatic Veno-Occlusive Disease (2015) (3)
- 30th Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2015). (2015) (3)
- Natural killer cell consolidation for acute myelogenous leukemia: a cell therapy ready for prime time? (2010) (3)
- Mesenchymal stromal cell therapy induces high responses and survival in children with steroid refractory GVHD and poor risk biomarkers (2021) (3)
- Unrelated donor α/β T cell– and B cell–depleted HSCT for the treatment of pediatric acute leukemia (2021) (3)
- Potent Efficacy of Combined PI3K/mTOR and JAK or SRC/ABL Inhibition in Philadelphia Chromosome-like Acute Lymphoblastic Leukemia (2015) (3)
- Patient-reported quality of life (QOL) following CTL019 in pediatric and young adult patients (pts) with relapsed/refractory (r/r) b-cell acute lymphoblastic leukemia (B-ALL). (2017) (3)
- Impact of Humoral Immunogenicity (Anti-mCAR19 Antibodies) on CTL019 Cellular Kinetics, Efficacy, and Safety (2017) (3)
- Potential Role of IFNγ Inhibition in Refractory Cytokine Release Syndrome Associated with CAR T-cell Therapy. (2021) (3)
- Inpatient and Intensive Care Unit Resource Utilization after CD19-Targeted Chimeric Antigen Receptor T-Cell Therapy (CART19) for Pediatric Acute Lymphoblastic Leukemia (ALL) (2020) (3)
- Hypogammaglobulinemia and Infection Risk in Chronic Lymphocytic Leukemia (CLL) Patients Treated with CD19-Directed Chimeric Antigen Receptor T (CAR-T) Cells (2020) (3)
- Monitoring of Minimal Residual Disease before and after Allogeneic Stem Cell Transplantation Childhood ALL - a Retrospective Assessment on Behalf of the PDWP of the EBMT, the COG, PBMTC, the I-BFM and the Westhafen-Intercontinental-Group (2016) (3)
- Biomarker correlates with response to NY-ESO-1 TCR T cells in patients with synovial sarcoma (2022) (3)
- Targeting mTOR Signaling Leads To Complete and Durable Responses In Children With Multi-Lineage Autoimmune Cytopenias, Including ALPS, SLE, Evans and CVID (2013) (2)
- Prediction of Patients at Risk of CD19Neg Relapse Following CD19-Directed CAR T Cell Therapy in B Cell Precursor Acute Lymphoblastic Leukemia (2019) (2)
- 69: Sirolimus (SRL)-Based GVHD Prophylaxis After TBI/TT/Cy Allogeneic HSCT in Pediatric Patients with HR All: Results of a Multi-Institutional Pilot Study (2008) (2)
- Abstract 1537: Anti-CD19 ARTEMIS™ T cells prevent excessive inflammatory cytokine release, including IL-6, in a co-culture model of CRS (2018) (2)
- S1618 TISAGENLECLEUCEL APPEARS EFFECTIVE AND SAFE IN PEDIATRIC AND YOUNG ADULT PATIENTS WITH RELAPSED/REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA WITH HIGH-RISK CYTOGENETIC ABNORMALITIES (2019) (2)
- Single-cell antigen-specific activation landscape of CAR T infusion product identifies determinants of CD19 positive relapse in patients with ALL (2021) (2)
- Childhood Leukemia (2020) (2)
- Minimally Ex Vivo Manipulated Gene-Modified T Cells Display Enhanced Tumor Control (2016) (2)
- A Randomized Trial of Sirolimus-Based Graft Versus Host Disease (GVHD) Prophylaxis After Hematopoietic Stem Cell Transplantation (HSCT) in Selected Patients with CR1 and CR2 ALL: Results From Children's Oncology Group Study ASCT0431 (2011) (2)
- Autologous genetically engineered NY-ESO-1c259T in HLA-A*02:01, HLA*02:05 and HLA*02:06 positive patients with NY-ESO-1 expressing tumors. (2016) (2)
- Impact of poverty and neighborhood opportunity on outcomes for children treated with CD19-directed CAR T-cell therapy. (2022) (2)
- Open label non-randomized multi-cohort pilot study of genetically engineered NY-ESO-1 specific NY-ESO-1c259 SPEAR T-cellsTM in HLA-A*02+ patients with synovial sarcoma (NCT01343043) (2016) (2)
- Defibrotide for the Treatment of Patients with Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome with/without Multi-Organ Dysfunction Following Chemotherapy: Results from an Ongoing Expanded Access Program (2015) (2)
- Pharmacokinetics and Pharmacodynamics of Tocilizumab for the Management of Cytokine Release Syndrome (CRS) in Pediatric and Young Adult Patients with Relapsed/Refractory (R/R) B-Cell Acute Lymphoblastic Leukemia (B-ALL) Treated with CAR T-Cell Therapy, CTL019 (2017) (2)
- Targeting mTOR Signaling Is An Effective Treatment Strategy for IKAROS and JAK Kinase Mutated Acute Lymphoblastic Leukemia (2010) (2)
- Bioluminescent Tracking of Human and Mouse Acute Lymphoblastic Leukemia Reveals Potent Immunogenicity of Luciferase In Some Preclinical Models of Leukemia (2010) (2)
- Abstract 4707: Genetically engineered NY-ESO-1-specific T cells in HLA-A2+ patients with synovial sarcoma (2015) (2)
- Timing of initiation of defibrotide (DF) post-diagnosis of hepatic veno-occlusive disease/sinusoidal obstruction syndrome (VOD/SOS) after hematopoietic stem cell transplantation (HSCT): Final data from an expanded-access protocol. (2017) (2)
- Cytoplasmic micro heavy chain confers sensitivity to dexamethasone-induced apoptosis in early B-lineage acute lymphoblastic leukemia. (2002) (2)
- Abstract 3143: Alternative splicing of CD19 mRNA in leukemias escaping CART-19 immunotherapy eliminates the cognate epitope and contributes to treatment failure (2015) (2)
- Effective targeting of primary human acute myeloid leukemia using anti-CD123 chimeric antigen receptor engineered T cells (2013) (2)
- Pilot study of redirected autologous T cells engineered to contain anti-CD19 attached to TCRζ and 4-1BB signaling domains in patients with chemotherapy-resistant or -refractory CD19+ leukemia and lymphoma. (2013) (2)
- Improved Anti-Leukemia Activities of Adoptively Transferred T Cells Expressing Bites (2015) (2)
- Subcutaneous Immunoglobulin Replacement Following CD19-Specific Chimeric Antigen Receptor-T Cell Therapy for B-Cell Acute Lymphoblastic Leukemia (2018) (2)
- Treatment of Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome (VOD/SOS) Post-Hematopoietic Stem Cell Transplantation (HSCT) in Patients with Acute Leukemias: A Subgroup Analysis from the Defibrotide Expanded-Access Program (2016) (2)
- Comprehensive Serum Proteome Profiling of Cytokine Release Syndrome and Immune Effector Cell Associated Neurotoxicity Syndrome in B-Cell ALL Patients Receiving CART19. (2022) (2)
- Cardiac effects of chimeric antigen receptor (CAR) T-cell therapy in children. (2017) (2)
- Efficacy and safety of defibrotide (DF) to treat hepatic veno-occlusive disease/sinusoidal obstruction syndrome (VOD/SOS) after primary chemotherapy (CT): A post hoc analysis of final data. (2017) (2)
- Sustained Functional T Cell Persistence and B Cell Aplasia Following CD19-Targeting Adoptive T Cell Immunotherapy for Relapsed, Refractory CD19+ Malignacy (2012) (2)
- Distinct Bioenergetic Features of Human Invariant Natural Killer T Cells Enable Retained Functions in Nutrient-Deprived States (2021) (2)
- Impaired tumor death receptor signaling drives resistance to CAR T cell therapy (2019) (2)
- Partially CD3+-depleted unrelated and haploidentical donor PSCT has favorable GVHD and survival rates in pediatric hematologic malignancy. (2019) (2)
- Trends in Inpatient and Intensive Care Resource Utilization after Chimeric Antigen Receptor T Cell Therapy for Pediatric Acute Lymphoblastic Leukemia from 2012-2019 (2019) (2)
- Rapid T Cell Recovery and Possible Auto-GVHD Following Adoptive Transfer of Ex-Vivo Costimulated Autologous T Cells at Day +2 Post-Transplant. (2007) (1)
- Complete Versus Incomplete Hematologic Recovery after CAR T Cell Therapy: Implications for Relapse Free Survival and Overall Survival in Pediatric and Young Adult Patients with Relapsed/Refractory B-ALL (2021) (1)
- Defibrotide for the Treatment of Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome with Multi-Organ Dysfunction: Final Results from a Pivotal, Historically Controlled, Phase 3 Trial (2015) (1)
- Effect of ONC201 and bortezomib on apoptosis in non-Hodgkin's lymphoma (NHL) xenografts. (2017) (1)
- Murine Ultrasonography Confirms That Rapamycin Is Effective Against Autoimmune Lymphoproliferative Syndrome (ALPS). (2005) (1)
- Impact of CAR T-cell product viability on B-cell lymphoid malignancy outcomes (2019) (1)
- Refining megatherapy, improving outcome in neuroblastoma. (2017) (1)
- The role of peritoneal drainage in veno-occlusive disease in pediatric patients post hematopoietic stem cell transplant (2018) (1)
- Pooled Treatment Analysis of Pediatric Patients with Defibrotide for Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome and Multi-Organ Dysfunction Following Hematopoietic Stem Cell Transplant (2015) (1)
- Statistical Considerations for Analyses of Time-To-Event Endpoints in Oncology Clinical Trials: Illustrations with CAR-T Immunotherapy Studies (2022) (1)
- Abstract 2642: Preclinical efficacy of daratumumab in acute lymphoblastic leukemia (2017) (1)
- Comprehensive Secretome Profiling Elucidates Novel Disease Biology and Identifies Pre-Infusion Candidate Biomarkers to Predict the Development of Severe Cytokine Release Syndrome in Pediatric Patients Receiving CART19 (2021) (1)
- Role of m Heavy Chain in B Cell Development. I. Blocked B Cell Maturation But Complete Allelic Exclusion in the Absence of Iga/b (1998) (1)
- Corrigendum to "Insulin-like Growth Factor-binding Protein-7 (IGFBP7): A Promising Gene Therapeutic for Hepatocellular Carcinoma (HCC)". (2015) (1)
- Face and Thigh Swelling in a 6-Year-Old Girl (2003) (1)
- Low rate of subsequent malignant neoplasms after CD19 CAR T-cell therapy (2022) (1)
- Abstract 510: Impact of tisagenlecleucel product attributes on clinical outcomes in pediatric and young adult patients with relapsed or refractory acute lymphoblastic leukemia (r/r ALL) (2021) (1)
- Chimeric Immunoreceptor (T-Body) Targeting of Acute B-Cell Lymphoblastic Leukemia (B-ALL) through Lentivirus Engineering of Primary Human T Cells. (2006) (1)
- Early Events in B‐Cell Activation: Binding of Antigen to Antigen‐Specific Cells Results in a Phosphatidylinositol Response (1987) (1)
- malignancies Antibody-modified T cells: CARs take the front seat for hematologic (2014) (1)
- Corrigendum to "Chimeric Receptors Containing CD137 Signal Transduction Domains Mediate Enhanced Survival of T Cells and Increased Antileukemic Efficacy In Vivo". (2015) (1)
- Generation of a multi-antigen-directed immune response for durable control of acute lymphoblastic leukemia (2018) (1)
- Pooled Analysis of Day +100 Survival for Defibrotide-Treated Patients with Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome (VOD/SOS) and Ventilator or Dialysis Dependence Following Hematopoietic Stem Cell Transplantation (HSCT) (2018) (1)
- #504 Tandem high dose therapy for children with high‐risk neuroblastoma and metastatic sarcomas (1998) (1)
- Pre-Clinical Development Of a Novel Chimerical Antigen Receptor Targeting High-Risk Pediatric ALL Over-Expressing Tslpr (2013) (1)
- Series ANTIBODY DERIVATIVES AS NEW THERAPEUTICS FOR HEMATOLOGIC MALIGNANCIES Antibody-modi fi ed T cells : CARs take the front seat for hematologic malignancies (2014) (1)
- A novel antibody-TCR (AbTCR) T-cell therapy is safe and effective against CD19-positive relapsed/refractory B-cell lymphoma (2022) (1)
- myeloablation using chimeric antigen receptor Preclinical targeting of human acute myeloid leukemia (2014) (1)
- In vivo monitoring of JAK/STAT and PI3K/mTOR signal transduction inhibition in pediatric CRLF2-rearranged acute lymphoblastic leukemia (ALL). (2012) (1)
- Efficacy and Safety of Defibrotide in Pediatric Patients with Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome (VOD/SOS) after Hematopoietic Stem Cell Transplantation (HSCT): Final Results from the Expanded-Access Program (2017) (1)
- Thoracic duct lymphatic fluid harbors phenotypically naive T cells for use in adoptive T-cell therapy. (2020) (1)
- Reviewers for the Journal, January-June 2016. (2016) (1)
- Targeting Notch Signaling as a Safe and Effective Treatment for Autoimmune and Lymphoproliferative Diseases. (2006) (1)
- Complete Responses in Patients with Autoimmune Lymphoproliferative Syndrome (ALPS) Using the mTOR Inhibitor Sirolimus (rapamycin) (2008) (1)
- Inhibiting PIM-1 Is Effective in Vitro and in Vivo against ALL: A Novel Mechanistic and Potentially Clinically Relevant Druggable Target. (2008) (1)
- Is G‐CSF‐mobilized peripheral stem cell harvest harmful?—Response (2007) (1)
- Favorable Chronic Graft-Versus-Host-Disease (GVHD), Event-Free (EFS), and Overall Survival (OS) Rates Following Partially CD3-Depleted Alternative Donor Peripheral Stem Cell Transplantation (PSCT) for Pediatric Hematologic Malignancies (2016) (1)
- Gene expression signatures of response to anti-CD19 chimeric antigen receptor (CAR) T-cell therapy in patients with CLL and ALL. (2017) (1)
- Successful Engraftment Using Varied Stem Cell Sources, Low Toxicity, and Long-Term Survival Using a Bu/Flu/ATG Reduced Intensity Allogeneic Transplantation in High Risk Pediatric Patients Ineligible for Myelablative Therapy: Results of the Pediatric Blood and Marrow Transplant Consortium (PBMTC) Stu (2007) (1)
- Issues in Pediatric Peripheral Blood Stem-Cell Collection (2006) (0)
- Defibrotide for the Treatment of Patients with Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome with/without Multi-Organ Dysfunction Following Chemotherapy: Subset Analysis Results from an Ongoing Expanded Access Program (2016) (0)
- acute lymphoblastic leukemia Targeting JAK1/2 and mTOR in murine xenograft models of Ph-like (2012) (0)
- Abstract 1309: Fitness of T cells for use in cellular therapy of pediatric malignancies (2015) (0)
- 11 High incidence of Epstein-Barr virus lymphoproliferative disease (EBV-LPD) after CD34-selected autologous peripheral blood stem cell transplant (PBSCT) in children with neuroblastoma(NB) (2003) (0)
- New stratification and treatment approaches in ALL-including CAR T Cell therapy (2019) (0)
- Removal of Normal Competition Increases Proliferation of Pre-Leukemic Cells in a Mouse Model of Pre-B Acute Lymphoblastic Leukemia. (2009) (0)
- Unrelated Donor Peripheral Stem Cell Transplantation (SCT) with Ex Vivo T Cell Receptor (TCR) αβ+/CD19+depletion for Pediatric Patients with Bone Marrow Failure (BMF) (2021) (0)
- IL-7 and Thymic Stromal Lymphopoietin (TSLP) Stimulate Proliferation of All Cells and Reverse mTOR Inhibitor-Induced Growth Inhibition, Suggesting a Role for IL-7Rα Signaling in All. (2004) (0)
- Defibrotide plus best standard of care compared with best standard of care alone for the prevention of sinusoidal obstruction syndrome (HARMONY): a randomised, multicentre, phase 3 trial. (2023) (0)
- Oncology and beyond: looking to the future of CAR-T and autologous cell therapy (2019) (0)
- Abstract 3505: Preclinical testing of mRNA engineered chimeric antigen receptor T cells: Comparison of a multi-infusion protocol to a single injection of stably expressed CARs in ALL xenograft models (2012) (0)
- Reply to W.H. Tong et al. (2023) (0)
- Automation Greatly Reduces Errors in Engraftment Dates Reported to CIBMTR (2022) (0)
- Sirolimus (SRL)-Based GVHD Prophylaxis After Allogeneic HSCT in Pediatric All Patients: Low NRM, Low Incidence of VOD, and Higher Than Expected EFS: Results of a Multi-Institutional Pilot Study (2009) (0)
- A Phase III Randomized Trial of G-CSF Stimulated Bone Marrow vs. Conventional Bone Marrow as a Stem Cell Source In Matched Sibling Donor Transplantation (2007) (0)
- CytotoxicResponsesControl T-LymphomaGrowth In Vitro and In Vivo (2013) (0)
- Title : Identification of Predictive Biomarkers for Cytokine Release Syndrome after Chimeric Antigen Receptor T cell Therapy for Acute Lymphoblastic Leukemia (2016) (0)
- Prognostic Value of Elafin in Acute Graft-Versus-Host Disease (2021) (0)
- Automation of Hematopoietic Cell Transplant Outcomes Reporting Leads to Dramatic Reduction of Errors Reported to Real-World Data Registry. (2023) (0)
- Abstract 4574: Use of CD19-targeted Chimeric Antigen Receptor-modified T (CART19) cells in ALL and CLL produce transient cytokine release syndrome (CRS), macrophage activation syndrome (MAS) and durable responses. (2013) (0)
- Vector Integration and Efficacy of CD19-Directed CAR T Cell Therapy in Acute Lymphoblastic Leukemia (ALL) and Chronic Lymphocytic Leukemia (CLL) (2018) (0)
- Stem cells support multiple cycles of high‐dose induction therapy: Lots from tots (2006) (0)
- Genetic mechanisms of target antigen loss in CAR19 therapy of acute lymphoblastic leukemia (2018) (0)
- Treatment of Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome (VOD/SOS) Post-Hematopoietic Stem Cell Transplantation (HSCT) in Patients with Neuroblastoma: Final Data from the Defibrotide Expanded-Access Program (2017) (0)
- Consensus Grading for Cytokine Release Syndrome and Neurologic D 224 X X Toxicity Associated with Immune Effector Cells (2019) (0)
- The utility of biomarkers in acute GVHD prognostication. (2023) (0)
- Chimeric Antigen Receptor (2015) (0)
- Targeting CD38 in T-ALL Upregulates the Targetable Polyamine Metabolism Pathway (2022) (0)
- A novel antibody-TCR (AbTCR) platform combines Fab-based antigen recognition with gamma/delta-TCR signaling to facilitate T-cell cytotoxicity with low cytokine release (2018) (0)
- Evaluating Efficacy and Safety of Tisagenlecleucel Reinfusion Following Loss of B-Cell Aplasia in Pediatric and Young Adult Patients with Acute Lymphoblastic Leukemia: HESTER Phase II Study (2021) (0)
- Updated Results from a Large, Ongoing, Treatment IND Study Using Defibrotide for Patients with Hepatic Veno-Occlusive Disease (2014) (0)
- Efficacy and Safety of Defibrotide in a Subset Analysis of Late-Onset Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome (VOD/SOS) Patients from an Ongoing, Expanded-Access Program (2016) (0)
- CD3/CD19 Depletion with Targeted T Cell Add-Back Results in Stable Engraftment and Minimal GVHD in Pediatric Patients with Bone Marrow Failure Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplantation (2016) (0)
- oligonucleotides In vivo control of acute lymphoblastic leukemia by immunostimulatory CpG (2013) (0)
- T-Cell Therapy Produced Prolonged Remission in Relapsed Pediatric ALL (2014) (0)
- Abstract A007: Comparison of pretreatment conditioning on efficacy in two cohorts of a pilot study of genetically engineered NY-ESO-1c259T-cells in patients with synovial sarcoma (2019) (0)
- Infusing Collaboration: Stem Cell Infusion Day Procedures (2023) (0)
- Correction for Bagashev et al., “CD19 Alterations Emerging after CD19-Directed Immunotherapy Cause Retention of the Misfolded Protein in the Endoplasmic Reticulum” (2022) (0)
- Resource utilization (RU) and toxicities after carboplatin/etoposide/melphalan (CEM) and busulfan/melphalan (BuMel) for autologous stem cell rescue (ASCR) in high-risk neuroblastoma (HRNB). (2015) (0)
- Abstract 2933: Pre-clinical model of eradication of B cell leukemia with lentiviral transduced anti-CD19 chimeric immunoreceptor-modified T cells (2010) (0)
- Abstract IA10: CARs for leukemia and beyond? (2015) (0)
- Advances in Brief Cytoplasmic Heavy Chain Confers Sensitivity to Dexamethasone-induced Apoptosis in Early B-lineage Acute Lymphoblastic Leukemia 1 (2002) (0)
- Impact on Outcomes of Baseline Bilirubin in Patients with Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome Receiving Defibrotide Treatment: A Post-Hoc Analysis (2016) (0)
- Stem-Cell Transplantation in Neuroblastoma (2006) (0)
- iNKTCell CytotoxicResponsesControl T-LymphomaGrowth In Vitro and In Vivo (2013) (0)
- Altenative Donor Peripheral Stem Cell Transplant (PSCT) with CD3+ Depletion and CD3+ Addback for Pediatric Patients with Leukemias (2009) (0)
- Delivering Post Hematopoietic Stem Cell Transplant (HSCT) Vaccines in a Pediatrician's Office Versus Specialty Care Setting (2020) (0)
- Ikaros Mediates Antigen Escape Following CD19 CAR T Cell Therapy in r/r B-ALL (2021) (0)
- Monitoring of MRD before and after Allogeneic Hematopoietic Cell Transplantation (HCT) of Childhood ALL by FC and RQ-PCR: A Retrospective Assessment on Behalf of the Pdwp of the Ebmt, the Cog, the Pbmtc, the I-Bfm and the Westhafen-Intercontinental-Group (2017) (0)
- Abstract 909: Single-cell multi-omics reveals type-2 function and metabolic fitness in maintaining CAR T cell longevity associated with 8-year leukemia remission (2023) (0)
- Distinct bioenergetic features of human invariant natural killer T (iNKT) cells enable retained functions in nutrient-deprived states (2021) (0)
- Immune-mediated depletion of pre-leukemic cells delays disease onset in a murine spontaneous leukemia model (88.17) (2009) (0)
- Safety and Efficacy of CTX001 in Patients with Transfusion-Dependent β-Thalassemia (TDT) or Sickle Cell Disease (SCD): Early Results from the Climb THAL-111 and Climb SCD-121 Studies of Autologous CRISPR-Cas9-Modified CD34+ Hematopoietic Stem and Progenitor Cells (HSPCs) (2021) (0)
- CAR T for Pediatric ALL: What’s Next? (2021) (0)
- mTOR Inhibitors Induce Apoptosis and Inhibit Growth of Primary Adult Human ALL in Xenograft and Tissue Culture Models. (2004) (0)
- Defibrotide for Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome with Multi-Organ Dysfunction: A Concordance Analysis Between Day+100 Complete Response and Survival (2016) (0)
- Identification of Cell Populations Associated with CD19Neg Relapse Following CAR T Cell Therapy in Acute Lymphoblastic Leukemia (2021) (0)
- Improving and Maintaining Responses in Pediatric B–Cell Acute Lymphoblastic Leukemia Chimeric Antigen Receptor–T Cell Therapy (2021) (0)
- Unrelated Donor (URD) or Partially Matched Related Donor (PMRD) Peripheral Stem Cell Transplant (PSCT) with CD34+ Selection and CD3+ Addback for Pediatric Patients with Leukemias. (2004) (0)
- CpG Oligonucleotides Induce Anti-Leukemia Activity in a Syngeneic Murine Model of Acute Lymphoblastic Leukemia. (2007) (0)
- Procedes de traitement de la leucemie lymphoide aigue (2003) (0)
- combination to treat acute lymphoblastic leukemia mTOR inhibitors are synergistic with methotrexate: an effective (2013) (0)
- Chimeric Antigen Receptor T Cells for Leukemias in Children: Methods, Data, and Challenges (2018) (0)
- Impact of diagnostic and end-of-induction Curie scores in tandem autologous hematopoietic cell transplant for patients with high-risk neuroblastoma: A report from the Children’s Oncology Group. (2022) (0)
- iNKTCellCytotoxicResponsesControlT-LymphomaGrowth In Vitro and In Vivo (2013) (0)
- DURABLE IMMUNE-MEDIATED PROTECTION FROM ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) IS INDUCED BY CPG OLIGODEOXYNUCLEOTIDES (CPG ODN) IN A SYNGENEIC MOUSE MODEL (2009) (0)
- Ex Vivo T-Cell Receptor αβ +/CD19 +depletion of Peripheral Stem Cell Grafts for Pediatric Patients with Bone Marrow Failure (BMF) Undergoing Unrelated Donor Transplantation (2021) (0)
- 232: Sirolimus, Tacrolimus and Fluconazole Pharmacokinetics in Pediatric BMT Recipients (2008) (0)
- PI3-Kinase Inhibition Decreases the Proliferation of ALL Cells, Potentiates mTOR Inhibition, and Abrogates Growth Factor-Mediated Reversal of mTOR Inhibition. (2006) (0)
- Characterization of Leukemic Resistance to CD19-Targeted CAR T-cell Therapy through Deep Genomic Sequencing (2022) (0)
- ALL-026: Evaluating Efficacy and Safety of Tisagenlecleucel Reinfusion Following Loss of B-Cell Aplasia in Pediatric and Young Adult Patients with Acute Lymphoblastic Leukemia: HESTER Phase II Study (2021) (0)
- Tisagenlecleucel for treatment of children and young adults with relapsed/refractory B cell acute lymphoblastic leukemia (2020) (0)
- Partial T cell depletion for unrelated donor BMT for children with severe aplastic anemia (SAA): engraftment with minimal GVHD (2004) (0)
- Abstract 509: Conversion of cellular kinetic data for chimeric antigen receptor T-cell therapy (CAR-T) into interpretable units (2021) (0)
- The MAGIC Algorithm Probability (MAP): A Novel Laboratory Biomarker for the Response to Treatment of Acute Graft-Versus-Host Disease (2019) (0)
- Abstract 3972: Carpet bombing with CARs: Influence of dose, timing, lymphodepletion and costimulatory domain on efficacy of mRNA engineered anti-CD19 Chimeric Antigen Receptor T cells in preclinical xenograft models. (2013) (0)
- Epitope Spreading Is Required for Long-Term Protection Against Acute Lymphoblastic Leukemia (2014) (0)
- Generation of long-term protection from acute lymphoblastic leukemia (ALL) by an immune stimulant in a syngeneic murine model (41.21) (2009) (0)
- Successful Purging of Stem Cell Products Using CD34 Selection (2003) (0)
- Post Hoc Analysis of Defibrotide for Treatment of Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome Post-Hematopoietic Stem Cell Transplantation in Subgroups of Patients with and Without Leukemia (2017) (0)
- De Novo Late Acute Gvhd: Incidence, Outcomes, and Impact of Biomarkers Compared to Classic Acute Gvhd (2023) (0)
- Humoral Immunity and Plasma Cell Changes in Patients Responding to CD19-Specific Chimeric Antigen Receptor (CAR)-Modified T-Cell Adoptive Immunotherapy (2014) (0)
- Induction of resistance to chimeric antigen receptor T cell therapy by transduction of a single leukemic B cell (2018) (0)
- Abstract B20: Innate and adaptive immune control of neoantigen-bearing acute lymphoblastic leukemia (ALL) enhanced by epitope spread (2014) (0)
- Abstract B33: Toll-like receptor ligands delay acute lymphoblastic leukemia onset via depletion of pre-leukemic cells (2014) (0)
- Improved Relapse-Free Survival (RFS) for Pediatric and Young Adult Patients with Relapsed or Refractory (R/R) B-Cell Acute Lymphoblastic Leukemia (B-ALL) and Low or Intermediate Preinfusion Disease Burden Treated with Tisagenlecleucel: Results from the CIBMTR Registry (2023) (0)
- Final Analysis of Day +100 Survival by Prior Hematopoietic Stem Cell Transplant Type From an Expanded-Access Study of Defibrotide for Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome (2018) (0)
- 3:45 PM Abstract No. 196 Nontunneled central apheresis catheter placement for T-cell harvesting in chimeric antigen receptor therapy: 5-year experience at a pediatric institution (2018) (0)
- 69: Therapeutic monitoring of sirolimus is essential in pediatric BMT recipients (2007) (0)
- Allogeneic Hematopoietic Cell Transplantation (HCT) for Neuroblastoma (NB): The CIBMTR Experience (2011) (0)
- modified T cells - myeloablation using chimeric antigen receptor Preclinical targeting of human acute myeloid leukemia and (2014) (0)
- #418 TNP-470 inhibits the growth rate and tumorigenicity of human neuroblastoma xenografts (1999) (0)
- disease Targeting Notch signaling in autoimmune and lymphoproliferative (2013) (0)
- Abstract 2790: The monocyte lineage is required for production of clinically relevant interleukin-6 (IL-6) during chimeric antigen receptor (CAR) T cell cytotoxicity (2014) (0)
- Corrigendum to "Advances in T-cell therapy for ALL" [Best Pract Res Clin Haematol 27 (2014) 222-228]. (2016) (0)
- Anti-CD123 chimeric antigen receptor redirected T cells for relapsed B-cell acute lymphoblastic leukemia (2014) (0)
- CAR-T in the clinic: drive with care (2018) (0)
- A Novel Model of Immune-Mediated Disease Equilibrium in Acute Lymphoblastic Leukemia (2012) (0)
- Abstract 997: Targeting the Jak/Stat signaling pathway is highly effective in xenograft models of early T cell precursor (ETP) acute lymphoblastic leukemia (ALL) (2014) (0)
- Evaluation of Defibrotide (DF) in the Treatment of Hepatic Veno-Occlusive Disease (VOD) in Non-Stem Cell Transplant (non-SCT) Chemotherapy Patients (pts): Results From the Treatment IND (T-IND) Expanded Access Protocol and the Compassionate Use Program (CUP). (2012) (0)
- #630 Role of the pre‐B cell receptor complex in B cell development: differential signaling via α/β and surrogate light chain (1998) (0)
- Angiogenesis Inhibitor TNP-470 During Bone Marrow Transplant and in Minimal Residual Disease (2003) (0)
- Treatment of Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome (VOD/SOS) Post-Hematopoietic Stem Cell Transplantation (HSCT) in Patients with Neuroblastoma: Final Data from the Defibrotide Expanded-Access Program (T-IND) (2018) (0)
- Unrelated and Haploidentical Hematopoietic Stem Cell Transplantation (HSCT) Using TCR αβ+CD3+Depletion in Pediatric Patients with Hematologic Malignancies (2016) (0)
- Immune Profiling Suggests an IGH Signaling-Dependent Subtype of Aggressive B-ALL (2012) (0)
- Two Partial T Cell Depletion Strategies for Unrelated Donor Peripheral Stem Cell Transplantation are Associated with Excellent Outcomes for Pediatric Patients with Bone Marrow Failure (BMF) (2018) (0)
- Reply. (2019) (0)
- Timing of Initiation of Defibrotide Post-Diagnosis of Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome (VOD/SOS) after Hematopoietic Stem Cell Transplantation (HSCT): Exploratory Age-Group Analysis From an Expanded Access Study (2017) (0)
- Impact on Outcomes of Baseline Bilirubin in Patients with Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome (VOD/SOS) after Hematopoietic Stem Cell Transplant (HSCT) Receiving Defibrotide Treatment: A Post-Hoc Analysis (2017) (0)
- Evaluation of IL-7 signaling as a therapeutic target in a transgenic mouse model Effect of rapamycin on progenitor B cell malignancies (2002) (0)
- Low Rates of Toxicity, GVHD, and Relapse Using Sirolimus (SRL)-Based GVHD Prophylaxis in Pediatric Related and Unrelated Transplant Recipients with High-Risk ALL. (2006) (0)
- 74: Sirolimus (SRL)-based GVHD prophylaxis to decrease relapse in pediatric related and unrelated transplant recipients with very high-risk all: Preliminary results of a multi-institutional pilot study (2007) (0)
- ‘Off-the-shelf’ allogeneic CAR T cells: development and challenges (2020) (0)
- CD22-Targeted CAR-Modified T-Cells Safely Induce Remissions in Children and Young Adults with Relapsed, CD19-Negative B-ALL after Treatment with CD19-Targeted CAR T-Cells (2022) (0)
- Efficacy and Safety of Defibrotide in Pediatric Patients with Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome (VOD/SOS) after Hematopoietic Stem Cell Transplantation (HSCT): Final Results From the Expanded-Access Program (T-IND) (2018) (0)
- 58: mTOR inhibitors (MTI) are synergistic with methotrexate: An effective combination to both prevent post-HSCT relapse of all and prevent GVHD (2007) (0)
- Signal Transduction Inhibitors in Lymphoproliferative Diseases (LPD). (2008) (0)
- Targeting HMG-CoA Reductase in Acute Lymphoblastic Leukemia (ALL): Statins Inhibit Proliferation and Induce Apoptosis in ALL Cells (2008) (0)
- Durable Remissions with Control of Cytokine Release Syndrome (CRS) Using T Cells Expressing CD19 Targeted Chimeric Antigen Receptor (CAR) CTL019 to Treat Relapsed/Refractory (R/R) Acute Lymphoid Leukemia (ALL) (2016) (0)
This paper list is powered by the following services:
Other Resources About Stephan Grupp
What Schools Are Affiliated With Stephan Grupp?
Stephan Grupp is affiliated with the following schools:
